These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32665698)

  • 1. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
    Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ
    Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
    Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
    Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins inhibit blastocyst formation by preventing geranylgeranylation.
    Alarcon VB; Marikawa Y
    Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
    De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
    Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
    Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
    Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.
    Du T; Song Y; Ray A; Chauhan D; Anderson KC
    Leukemia; 2021 Feb; 35(2):550-561. PubMed ID: 32424294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
    Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
    Biochem Biophys Res Commun; 2008 Sep; 374(2):309-14. PubMed ID: 18625202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
    Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
    Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins.
    Yu R; Longo J; van Leeuwen JE; Mullen PJ; Ba-Alawi W; Haibe-Kains B; Penn LZ
    Cancer Res; 2018 Mar; 78(5):1347-1357. PubMed ID: 29229608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.
    Xia Z; Tan MM; Wong WW; Dimitroulakos J; Minden MD; Penn LZ
    Leukemia; 2001 Sep; 15(9):1398-407. PubMed ID: 11516100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis.
    Nagashima T; Okazaki H; Yudoh K; Matsuno H; Minota S
    Arthritis Rheum; 2006 Feb; 54(2):579-86. PubMed ID: 16447234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
    Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
    Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocytic pathway inhibition attenuates extracellular vesicle-induced reduction of chemosensitivity to bortezomib in multiple myeloma cells.
    Tu C; Du Z; Zhang H; Feng Y; Qi Y; Zheng Y; Liu J; Wang J
    Theranostics; 2021; 11(5):2364-2380. PubMed ID: 33500730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma.
    Clendening JW; Pandyra A; Li Z; Boutros PC; Martirosyan A; Lehner R; Jurisica I; Trudel S; Penn LZ
    Blood; 2010 Jun; 115(23):4787-97. PubMed ID: 20360469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.
    Tanaka T; Tatsuno I; Uchida D; Moroo I; Morio H; Nakamura S; Noguchi Y; Yasuda T; Kitagawa M; Saito Y; Hirai A
    J Neurosci; 2000 Apr; 20(8):2852-9. PubMed ID: 10751437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
    Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
    Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
    Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
    Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
    Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
    Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
    Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
    Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.